MG132, a proteasome inhibitor, enhances LDL uptake in HepG2 cells in vitro by regulating LDLR and PCSK9 expression
文献类型：期刊论文
| 作者 | Yan, Hong; Ma, Yan-ling; Gui, Yu-zhou; Wang, Shu-mei; Wang, Xin-bo; Gao, Fei; Wang, Yi-ping
|
| 刊名 | ACTA PHARMACOLOGICA SINICA
 |
| 出版日期 | 2014-08 |
| 卷号 | 35期号:8页码:994-1004 |
| 关键词 | cholesterol homeostasis LDLR MG132 proteasome inhibition PKC PCSK9 pravastatin HepG2 cells |
| ISSN号 | 1671-4083 |
| DOI | 10.1038/aps.2014.52 |
| 文献子类 | Article |
| 英文摘要 | Aim: Expression of liver low-density lipoprotein receptor (LDLR), a determinant regulator in cholesterol homeostasis, is tightly controlled at multiple levels. The aim of this study was to examine whether proteasome inhibition could affect LDLR expression and LDL uptake in liver cells in vitro. Methods: HepG2 cells were examined. Real-time PCR and Western blot analysis were used to determine the mRNA and protein levels, respectively. Dil-LDL uptake assay was used to quantify the LDLR function. Luciferase assay system was used to detect the activity of proprotein convertase subtilisin/kexin type 9 (PCSK9, a major protein mediating LDLR degradation) promoter. Specific siRNAs were used to verify the involvement of PCSK9. Results: Treatment of HepG2 cells with the specific proteasome inhibitor MG132 (0.03-3 mu mol/L) dose-dependently increased LDLR mRNA and protein levels, as well as LDL uptake. Short-term treatment with MG132 (0.3 mu mol/L, up to 8 h) significantly increased both LDLR mRNA and protein levels in HepG2 cells, which was blocked by the specific PKC inhibitors GF 109203X, Go 6983 or staurosporine. In contrast, a longer treatment with MG132 (0.3 mu mol/L, 24 h) did not change LDLR mRNA, but markedly increased LDLR protein by reducing PCSK9-mediated lysosome LDLR degradation. Furthermore, MG132 time-dependently suppressed PCSK9 expression in the HepG2 cells through a SREBP-1c related pathway. Combined treatment with MG132 (0.3 mu mol/L) and pravastatin (5 mu mol/L) strongly promoted LDLR expression and LDL uptake in HepG2 cells, and blocked the upregulation of PCSK9 caused by pravastatin alone. Conclusion: Inhibition of proteasome by MG132 in HepG2 cells plays dual roles in LDLR and PCSK9 expression, and exerts a beneficial effect on cholesterol homeostasis. |
| WOS关键词 | PROTEIN-KINASE-C ; SUBTILISIN/KEXIN TYPE 9 ; RECEPTOR ; CHOLESTEROL ; PATHWAY ; ELEMENT ; GENE ; TRANSCRIPTION ; EPSILON ; TARGET |
| WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| CSCD记录号 | CSCD:5206234 |
| WOS记录号 | WOS:000340510400002 |
| 出版者 | ACTA PHARMACOLOGICA SINICA |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/276957]  |
| 专题 | 药理学第一研究室 中科院受体结构与功能重点实验室 新药研究国家重点实验室 |
| 通讯作者 | Wang, Yi-ping |
| 作者单位 | Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Yan, Hong,Ma, Yan-ling,Gui, Yu-zhou,et al. MG132, a proteasome inhibitor, enhances LDL uptake in HepG2 cells in vitro by regulating LDLR and PCSK9 expression[J]. ACTA PHARMACOLOGICA SINICA,2014,35(8):994-1004. |
| APA | Yan, Hong.,Ma, Yan-ling.,Gui, Yu-zhou.,Wang, Shu-mei.,Wang, Xin-bo.,...&Wang, Yi-ping.(2014).MG132, a proteasome inhibitor, enhances LDL uptake in HepG2 cells in vitro by regulating LDLR and PCSK9 expression.ACTA PHARMACOLOGICA SINICA,35(8),994-1004. |
| MLA | Yan, Hong,et al."MG132, a proteasome inhibitor, enhances LDL uptake in HepG2 cells in vitro by regulating LDLR and PCSK9 expression".ACTA PHARMACOLOGICA SINICA 35.8(2014):994-1004. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。